Biomere’s scientists work across multiple therapeutic areas, including CNS diseases. Our team has developed deep expertise in dosing routes for both large and small animal models, as well as extensive experience with complex rodent models for oncology and metabolic disease studies.
A critical consideration in the preclinical evaluation of CNS-targeted therapies is the choice of dosing route. Systemic dosing often results in poor CNS distribution due to the blood-brain barrier (BBB), whereas tissue-specific dosing can significantly improve bioavailability in CNS tissues and cerebrospinal fluid (CSF).
The most commonly used CNS dosing routes in preclinical animal models, including rodents, rabbits, and non-human primates (NHPs), are:
Once a therapeutic is administered directly into CNS tissues, CSF sampling and analysis is the standard method for assessing drug exposure and biomarker levels. Serial CSF collection is facilitated by the placement of chronic indwelling ports, which enable repeated sampling in conscious animals and eliminate the need for multiple sedation events. Properly placed CSF ports also minimize sample contamination with red blood cells. Beyond chronic porting, Biomere’s expertise extends to direct-stick techniques targeting the lumbar and cisternal intrathecal space, for both IT dosing and CSF collection.
